Abstract CT033: TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) withEGFR-mutant,MET-amplified NSCLC after progression on prior third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)
Year: 2019
Type: conference-abstract
Source: Clinical Trials
Institutions: Massachusetts General Hospital, Seoul National University Bundang Hospital, National Cancer Center, National Cheng Kung University Hospital, National Taiwan University Hospital, Memorial Sloan Kettering Cancer Center, AstraZeneca (United Kingdom), Dana-Farber Cancer Institute, Yonsei University, Yonsei Cancer Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4231502686